FDA Inspection 1323466 — Guomin Xiao
The FDA completed an inspection of Guomin Xiao on Jun 4, 2026 in Hangzhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 4, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Hangzhou (China)
Additional Details
Clinical BA/BE